Nearly 20% of breast cancers are negative for ER/PR/HER2 markers and constitute a group of triple-negative breast cancers (TNBCs) that lacking targeted therapy and routinely are treated with chemotherapy regimens3,4. The gene discussed is PGR; the disease is breast carcinoma.